Aydien Cliff Omidvar v. HHS - DTaP, Dravet syndrome (2014)
Case summary [AI summaries can sometimes make mistakes]
On October 20, 2006, Esfandiar Santini and Laurie Omidvar, as legal representatives of their minor son Aydien Cliff Omidvar, filed a petition for compensation under the National Childhood Vaccine Injury Program. They alleged that the diphtheria-tetanus-acellular pertussis (DTaP) vaccine administered on November 7, 2003, caused or significantly aggravated Aydien's Dravet syndrome.
Aydien was born on July 6, 2003, and had a de novo mutation in the SCN1A gene, which is associated with Dravet syndrome. Approximately ten hours after receiving the DTaP vaccine at four months old, Aydien experienced his first seizures.
The initial diagnosis at the hospital was seizures due to DTaP immunization. Over the following months, Aydien continued to have seizures and was diagnosed with gross developmental delay.
Genetic testing confirmed the SCN1A mutation, which arose spontaneously and was not inherited from his parents. Petitioners' expert, Dr.
Jean-Ronel Corbier, a pediatric neurologist, proposed three theories: that children with SCN1A mutations are vulnerable to DTaP reactions, that the vaccine triggered earlier seizure onset leading to worse outcomes, and that the vaccine-induced prolonged first seizure damaged HCN channels, creating a cascade that worsened epilepsy. The respondent, represented by counsel Voris E.
Johnson, Jr., presented expert opinions from Dr. Max Wiznitzer, a pediatric neurologist, and Dr.
Gerald Raymond, a neurologist and geneticist. These experts opined that the SCN1A mutation was the sole cause of Aydien's condition and that the DTaP vaccine did not affect the degree of his developmental delay.
They cited several studies, including Berkovic, McIntosh, Tro-Baumann, and Brunklaus, which suggested that while vaccines might trigger the first seizure, the nature of the trigger does not affect the overall developmental outcome in individuals with SCN1A mutations. Dr.
Corbier's interpretation of these studies was found to be flawed and his testimony lacked credibility regarding the vaccine's impact on Aydien's long-term outcome. Special Master Christian J.
Moran denied compensation on December 15, 2014, finding the opinions of Drs. Raymond and Wiznitzer persuasive and Dr.
Corbier unpersuasive. The Special Master also concluded that petitioners failed to demonstrate that any vaccine-caused harm lasted more than six months, a statutory requirement for severity.
Petitioners appealed this decision to the Court of Federal Claims. Judge Susan G.
Braden affirmed the Special Master's decision on June 30, 2015. While Judge Braden noted a potential issue with the Special Master's reliance on Dr.
Wiznitzer's genetics opinions due to his lack of geneticist credentials, she affirmed the decision based on Dr. Raymond's independent expert support.
Judge Braden also raised an unexplored theoretical question about whether the vaccine could have caused the de novo mutation itself, but noted that this theory was not raised by the petitioners. Attorneys' fees and costs totaling $151,384.02 were awarded in installments across 2013 and 2015.
Theory of causation
Petitioners alleged that the DTaP vaccine administered on November 7, 2003, significantly aggravated Aydien Omidvar's pre-existing de novo SCN1A gene mutation, which causes Dravet syndrome. Their expert, Dr. Jean-Ronel Corbier, proposed three theories: (1) heightened susceptibility of SCN1A mutation carriers to DTaP adverse reactions; (2) vaccine-induced earlier onset of seizures, leading to worse long-term outcomes; and (3) vaccine-induced prolonged first seizure damaging HCN channels, initiating a 'seizures beget seizures' cascade. Respondent's experts, Drs. Max Wiznitzer and Gerald Raymond, contended that the SCN1A mutation was the sole cause of Aydien's condition and that the vaccine did not exacerbate it. They relied on studies (Berkovic, McIntosh, Brunklaus, Tro-Baumann) indicating that while vaccines can trigger the first seizure, the trigger's nature does not impact the ultimate developmental outcome in SCN1A mutation carriers. Special Master Christian J. Moran denied compensation, finding Dr. Corbier unpersuasive and Drs. Raymond and Wiznitzer persuasive, concluding the SCN1A mutation was the sole cause and that the severity requirement of more than six months of lasting harm was not met. The Court of Federal Claims affirmed, noting Dr. Raymond's genetic expertise supported the conclusion that the mutation was the sole cause, and also raised the unexplored theory of the vaccine causing the mutation itself. Attorneys' fees awarded: $151,384.02.